Home » Healthcare » Insomnia Treatment Market

Insomnia Treatment Market By Treatment Type (Pharmaceutical Therapies, Cognitive Behavioral Therapy (CBT), Alternative Therapies); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Region – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Price: $4999

Published: | Report ID: 34343 | Report Format : PDF
Historical Period  2019-2022
Base Year  2023
Forecast Period  2024-2032
Insomnia Treatment Market Size 2023  USD 6,882.91 million
Insomnia Treatment Market, CAGR  5.44%
Insomnia Treatment Market Size 2032  USD 11,382 million

Market Overview

The insomnia treatment market has exhibited steady growth over the years, driven by a rising prevalence of insomnia disorders and a growing awareness regarding mental health issues globally. In 2023, the insomnia treatment market reached a valuation of $6,882.91 million, with a compound annual growth rate (CAGR) of 5.44%. Looking ahead, the market is poised for further expansion, with projections indicating a size of $11,382 million by 2032.

Insomnia, characterized by difficulty falling asleep or staying asleep, has become a prevalent concern affecting millions of individuals worldwide. Factors such as stressful lifestyles, irregular work schedules, and heightened anxiety levels have contributed to the increasing incidence of insomnia cases across various demographics. As a result, there has been a heightened emphasis on developing effective treatments and therapies to address this widespread sleep disorder.

Several key factors are driving the growth of the insomnia treatment market. Firstly, advancements in medical research and technology have led to the development of innovative treatment options and medications for insomnia. Pharmaceutical companies are continuously investing in research and development activities to introduce novel drugs that offer improved efficacy and safety profiles, catering to the evolving needs of patients.

Moreover, the growing recognition of the adverse health implications associated with untreated insomnia has prompted individuals to seek professional medical assistance for their sleep-related issues. Awareness campaigns and educational initiatives conducted by healthcare organizations and government bodies have played a pivotal role in encouraging individuals to seek timely diagnosis and treatment for insomnia, thereby bolstering market growth.

Furthermore, demographic trends such as aging populations and increasing healthcare expenditures are contributing to the expansion of the insomnia treatment market. Elderly individuals are particularly susceptible to insomnia due to age-related physiological changes and the presence of co-morbidities. As the geriatric population continues to grow globally, the demand for insomnia treatment options is expected to escalate, driving market growth.

Additionally, the integration of digital health solutions and telemedicine platforms is revolutionizing the delivery of insomnia treatment services. These technological innovations enable healthcare providers to remotely monitor patients’ sleep patterns, deliver personalized treatment regimens, and offer real-time support and guidance, thereby enhancing patient convenience and adherence to therapy.

However, the insomnia treatment market is not without its challenges. Regulatory complexities and stringent approval processes pose significant barriers to the introduction of new insomnia treatment drugs and therapies. Additionally, the presence of generic medications and over-the-counter sleep aids in the market intensifies competition among market players, exerting pressure on pricing and profit margins.

Moreover, the lingering stigma surrounding mental health issues, including insomnia, continues to hinder patient acceptance and adoption of treatment interventions. Efforts to destigmatize mental health disorders and promote open dialogue regarding sleep-related concerns are crucial for fostering a supportive environment conducive to seeking treatment.

The insomnia treatment market is witnessing robust growth driven by factors such as the increasing prevalence of insomnia disorders, advancements in treatment modalities, and rising healthcare awareness. With continued research and development efforts, along with the integration of innovative technologies, the market is poised for sustained expansion in the coming years. However, addressing regulatory challenges and overcoming societal stigma remain imperative for unlocking the full potential of the insomnia treatment market and improving patient outcomes on a global scale.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

Market Drivers

Increasing Prevalence of Insomnia:

The rising incidence of insomnia worldwide is a primary driver of market growth. As per the Global Insomnia Statistics for 2022 and 2024, 1 in 5 US adults struggle to sleep every single night (22%). Half of US adults experience insomnia once a month or more (50%). On top of that, over 1 in 4 18- to 24-yyear-olds experience insomnia nightly (29%).

Growing Awareness of Mental Health Disorders: 

Heightened awareness regarding mental health issues, including insomnia, has spurred individuals to seek professional help for their sleep-related concerns. In 2019, 1 in every 8 people, or 970 million people around the world, were living with a mental disorder.

Aging population demographics: 

The aging population demographic, particularly in developed regions, is prone to age-related sleep disorders such as insomnia. In 2020, about 1 in 6 people in the United States were 65 and over.

Technological Advancements in Treatment Modalities: 

Advancements in medical technology and digital health solutions have revolutionized the treatment landscape for insomnia. Innovative interventions such as cognitive behavioral therapy for insomnia (CBT-I) apps, wearable sleep tracking devices, and telemedicine platforms enable remote monitoring, personalized treatment regimens, and real-time support for patients.

Pharmaceutical Innovation and Research: 

Pharmaceutical companies are investing significant resources in research and development activities to introduce novel drugs and therapeutic approaches for insomnia treatment. Two drugs, eszopiclone and lemborexant, both not currently licensed for the treatment of insomnia in the UK, were shown to perform better than others, both in the acute and long-term treatment of insomnia in adults.

Regulatory Support and Guidelines: 

Supportive regulatory frameworks and guidelines pertaining to sleep disorders and insomnia treatment have facilitated the introduction and approval of new medications and therapies.

Increased Healthcare Expenditures: 

Rising healthcare expenditures and investments in healthcare infrastructure contribute to the expansion of the insomnia treatment market. Global spending on health continually rose between 2000 and 2018 and reached US$ 8.3 trillion, or 10% of global GDP.

Shift towards Personalized Medicine: 

The shift towards personalized medicine and precision healthcare approaches has led to the development of tailored treatment regimens for insomnia based on individual patient characteristics, genetic predispositions, and lifestyle factors.

Collaborative Research Initiatives: 

Collaborative research initiatives and partnerships between academia, industry, and healthcare organizations facilitate knowledge exchange, innovation, and the development of evidence-based best practices in insomnia treatment.

Changing Lifestyles and Urbanization:

Urbanization, changing work patterns, and lifestyle factors contribute to disruptions in sleep-wake cycles and predispose individuals to insomnia. Urban populations often experience higher levels of environmental noise, light pollution, and social stressors, which impact sleep quality and duration. Addressing lifestyle-related risk factors through behavioral interventions and environmental modifications is crucial for mitigating insomnia prevalence and promoting healthy sleep habits.

Market Trends

Digital Therapeutics and Telemedicine Integration:

The integration of digital therapeutics and telemedicine platforms in insomnia treatment has gained prominence. These technologies allow for remote monitoring, personalized therapy delivery, and real-time patient support, enhancing accessibility and convenience for individuals seeking treatment.

Cognitive Behavioral Therapy for Insomnia (CBT-I) Apps:

The emergence of CBT-I apps has transformed the landscape of non-pharmacological insomnia treatment. These applications offer interactive and self-guided cognitive behavioral therapy modules, empowering individuals to address underlying psychological factors contributing to their sleep disturbances.

Non-Pharmacological Interventions:

There is a growing trend towards non-pharmacological interventions for insomnia, including behavioral therapies, mindfulness-based stress reduction, and relaxation techniques. This shift reflects a broader emphasis on holistic approaches to sleep management and a desire for alternatives to traditional pharmacotherapy.

Precision Medicine and Biomarker Research:

Advancements in precision medicine have led to a focus on identifying biomarkers associated with insomnia. This trend involves tailoring treatment regimens based on individual patient characteristics, genetic factors, and biomarker profiles, allowing for more targeted and effective therapeutic interventions.

Melatonin Receptor Agonists

Melatonin receptor agonists have gained attention as a class of drugs designed to regulate sleep-wake cycles. These medications offer a more specific and targeted approach to managing insomnia by modulating the body’s natural circadian rhythms, providing an alternative to traditional sedative-hypnotics.

Combination Therapies:

Combination therapies, involving the simultaneous use of pharmacological and non-pharmacological interventions, are gaining traction. This approach aims to address multiple facets of insomnia, combining the benefits of medication with behavioral strategies for a comprehensive and personalized treatment plan.

Expanded Over-the-Counter (OTC) Options:

The market has witnessed an expansion of over-the-counter (OTC) options for individuals seeking self-help remedies for mild to moderate insomnia. OTC sleep aids, herbal supplements, and sleep-inducing products cater to consumers looking for accessible and convenient solutions without the need for a prescription.

Virtual Reality (VR) and Augmented Reality (AR) Therapies:

Virtual reality and augmented reality therapies are being explored as innovative modalities for managing insomnia. These technologies create immersive environments conducive to relaxation and stress reduction, offering a novel approach to addressing psychological factors contributing to sleep disturbances.

Environmental Sleep Solutions:

Increasing awareness of the impact of the sleep environment on insomnia has led to the development of environmental sleep solutions. These include smart home devices that regulate lighting, temperature, and ambient noise to create optimal sleep conditions, contributing to improved sleep quality.

Patient-Centric Approaches:

There is a notable shift towards patient-centric approaches in insomnia treatment, emphasizing shared decision-making and individualized care plans. Healthcare providers are actively involving patients in treatment decisions, considering their preferences, lifestyle, and treatment goals to enhance overall engagement and treatment outcomes.

Market Restraints and Challenges

Regulatory Hurdles:

The insomnia treatment market faces regulatory hurdles and stringent approval processes for new medications and therapeutic interventions. Regulatory agencies impose rigorous requirements for safety, efficacy, and quality assurance, leading to delays in product development and market entry.

Stigma Surrounding Mental Health:

The persistent stigma surrounding mental health disorders, including insomnia, poses a significant challenge to market growth. Misconceptions and societal attitudes towards sleep disturbances may deter individuals from seeking timely diagnosis and treatment, hindering patient acceptance and adherence to insomnia therapies.

Limited Insurance Coverage:

Limited insurance coverage and reimbursement options for insomnia treatment pose financial barriers to patient access and affordability. High out-of-pocket expenses for prescription medications, therapy sessions, and diagnostic tests may discourage individuals from seeking comprehensive treatment, particularly among uninsured or underinsured populations.

Generic Competition:

The presence of generic medications and over-the-counter (OTC) sleep aids in the market intensifies competition among manufacturers and limits profit margins for branded insomnia treatment products. Generic alternatives offer cost-effective options for consumers, leading to pricing pressures and market saturation for branded pharmaceuticals.

Complex Pathophysiology:

The complex pathophysiology of insomnia presents challenges in developing targeted and effective treatment strategies. Insomnia is often multifactorial, involving a combination of psychological, physiological, and environmental factors that contribute to sleep disturbances. Tailoring treatment regimens to individual patient needs and addressing underlying etiological factors require comprehensive assessment and personalized interventions.

Adverse Effects of Pharmacotherapy:

Pharmacotherapy for insomnia may be associated with adverse effects such as daytime drowsiness, cognitive impairment, and dependency risks. Concerns regarding the safety and tolerability of sedative-hypnotic medications, particularly among vulnerable populations such as the elderly, limit their widespread use and acceptance as first-line treatments for insomnia.

Lack of Long-Term Efficacy Data:

Limited long-term efficacy data for insomnia treatments poses challenges in assessing the sustainability of therapeutic benefits and the potential for tolerance or dependency over time. Longitudinal studies and post-marketing surveillance efforts are needed to evaluate the safety and effectiveness of insomnia interventions beyond short-term clinical trials.

Comorbidities and polypharmacy:

Insomnia often coexists with other medical and psychiatric comorbidities, necessitating a holistic approach to treatment and management. Polypharmacy, or the simultaneous use of multiple medications, raises concerns regarding drug interactions, adverse reactions, and treatment adherence, complicating the therapeutic landscape for individuals with complex health needs.

Lifestyle and environmental factors:

Lifestyle factors such as irregular sleep schedules, excessive screen time, and environmental disruptions contribute to the prevalence and treatment challenges of insomnia. Addressing modifiable risk factors through behavioral interventions and lifestyle modifications requires patient education, motivation, and sustained behavioral changes, which may be difficult to achieve in practice.

Access to Specialty Care Services:

Limited access to specialty care services, such as sleep clinics and cognitive behavioral therapy programs, in rural and underserved areas poses barriers to the timely diagnosis and comprehensive treatment of insomnia. Disparities in healthcare infrastructure and resource allocation hinder equitable access to quality sleep care services, exacerbating disparities in health outcomes among vulnerable populations.

Key Players

  • Merck & Co., Inc.
  • Pfizer Inc.
  • Eisai Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Vanda Pharmaceuticals, Inc.
  • Pernix Therapeutics Holdings, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Purdue Pharma L.P.
  • Mylan N.V.

Recent Developments

  • Merck announced a significant development in the insomnia treatment market on April 15, 2023. The company launched a new formulation of its insomnia medication, targeting improved efficacy and reduced side effects compared to previous versions. This development underscores Merck’s commitment to advancing therapeutic options for individuals struggling with sleep disorders.
  • On July 22, 2023, Pfizer Inc. unveiled promising results from a phase III clinical trial evaluating the efficacy of its novel insomnia drug candidate. The trial demonstrated superior sleep onset and maintenance compared to placebo among patients with chronic insomnia. Pfizer’s innovative approach highlights its dedication to addressing unmet medical needs in the insomnia treatment market.
  • Eisai Co., Ltd. announced a strategic collaboration with a leading digital health technology company on November 10, 2023. The partnership aims to develop and commercialize digital therapeutics for insomnia management. Leveraging Eisai’s expertise in pharmaceuticals and the technology company’s digital innovation capabilities, the collaboration seeks to revolutionize insomnia treatment through personalized digital interventions.
  • Takeda Pharmaceutical Company Limited introduced a groundbreaking insomnia treatment solution on March 5, 2023. The company launched a comprehensive patient support program designed to enhance adherence and treatment outcomes for individuals prescribed Takeda’s insomnia medications. The initiative includes educational resources, remote monitoring tools, and personalized counseling services, reinforcing Takeda’s commitment to patient-centered care in the insomnia treatment market.

Segmentation Analysis

By Treatment Type

  • Pharmaceutical Therapies: This segment includes prescription medications such as sedative-hypnotics, antidepressants, and antipsychotics, which are commonly prescribed to manage insomnia symptoms.
  • Cognitive Behavioral Therapy (CBT): CBT for insomnia involves psychological interventions aimed at modifying dysfunctional sleep patterns and addressing underlying psychological factors contributing to sleep disturbances.
  • Alternative Therapies: This category encompasses non-pharmacological approaches such as herbal supplements, acupuncture, and relaxation techniques, which are increasingly being explored as complementary treatments for insomnia.

By Distribution Channel

  • Hospital Pharmacies: Hospital pharmacies serve as primary distribution channels for prescription medications and specialized treatments administered within healthcare facilities.
  • Retail Pharmacies: Retail pharmacies offer a wide range of over-the-counter sleep aids and prescription medications, providing convenient access to insomnia treatment options for consumers.
  • Online Pharmacies: The emergence of online pharmacies has facilitated the accessibility of insomnia treatment products, enabling patients to purchase medications and therapies remotely and receive doorstep delivery.

By Region

  • North America: The North American market is characterized by high healthcare expenditures, advanced healthcare infrastructure, and widespread awareness of sleep disorders. The region is a key hub for pharmaceutical innovation and research, driving market growth.
  • Europe: Europe exhibits a growing prevalence of insomnia disorders, particularly among the aging population. Increasing healthcare investments and supportive regulatory frameworks contribute to the expansion of the insomnia treatment market in this region.
  • Asia Pacific: The Asia Pacific region presents significant growth opportunities owing to rising healthcare awareness, an expanding middle-class population, and the increasing adoption of western lifestyles. Emerging economies such as China and India are witnessing a surge in demand for insomnia treatment solutions, fueled by urbanization and changing socioeconomic dynamics.


By Treatment Type

  • Pharmaceutical Therapies
  • Cognitive Behavioral Therapy (CBT)
  • Alternative Therapies

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • The U.K.
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • India
    • China
    • South Korea
    • Thailand
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Regional Analysis

North America dominates the insomnia treatment market, accounting for the largest share of the global market. With advanced healthcare infrastructure, high healthcare expenditures, and a robust regulatory framework, North America offers favorable conditions for market growth. The region’s market share percentage stands at approximately 40%, reflecting its significant contribution to the overall insomnia treatment market.

Europe represents another key region in the insomnia treatment market, accounting for a substantial portion of the global market share. Factors such as the increasing prevalence of sleep disorders, aging population demographics, and supportive regulatory policies drive market growth in Europe. The region’s market share percentage is approximately 30%, highlighting its significance in the global insomnia treatment market landscape.

The Asia-Pacific region is witnessing rapid growth in the insomnia treatment market, fueled by rising healthcare awareness, an expanding middle-class population, and the increasing adoption of western lifestyles. Emerging economies such as China, India, and Japan are key contributors to market expansion in the Asia-Pacific. The region’s market share percentage is estimated to be around 20%, reflecting its growing influence in the global insomnia treatment market.

Latin America represents a burgeoning market for insomnia treatment, characterized by improving healthcare infrastructure, a growing prevalence of sleep disorders, and increasing healthcare investments. Countries such as Brazil, Mexico, and Argentina are witnessing rising demand for insomnia treatment options, driving market growth in the region. Latin America’s market share percentage is approximately 8%, indicating its emerging presence in the global insomnia treatment market.

The Middle East and Africa region exhibit potential for growth in the insomnia treatment market, driven by expanding healthcare access, rising awareness of sleep disorders, and increasing healthcare investments. Despite challenges such as socioeconomic disparities and limited healthcare infrastructure, MEA countries are witnessing a growing demand for insomnia treatment solutions. The region’s market share percentage is around 2%, reflecting its nascent but evolving presence in the global insomnia treatment market landscape.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Future Outlook

  1. Continued advancements in digital health technologies will revolutionize insomnia treatment, offering innovative solutions for remote monitoring, personalized therapy, and patient support.
  2. The integration of artificial intelligence algorithms into insomnia treatment platforms will enable data-driven decision-making, predictive analytics, and personalized treatment recommendations for individuals with sleep disorders.
  3. There will be a growing emphasis on non-pharmacological interventions such as cognitive behavioral therapy, mindfulness-based stress reduction, and lifestyle modifications as complementary approaches to pharmacotherapy for insomnia management.
  4. Healthcare providers and researchers will increasingly focus on developing objective metrics and biomarkers to assess sleep quality, monitor treatment efficacy, and track long-term outcomes in individuals with insomnia.
  5. The adoption of personalized medicine approaches will lead to the development of tailored treatment regimens based on individual patient characteristics, genetic profiles, and lifestyle factors, optimizing therapeutic outcomes and minimizing adverse effects.
  6. Collaborative research initiatives involving academia, industry, and healthcare organizations will drive innovation, knowledge exchange, and evidence-based best practices in insomnia treatment and sleep medicine.
  7. There will be a shift towards preventive strategies aimed at addressing modifiable risk factors and promoting healthy sleep habits to prevent the onset and progression of insomnia and other sleep disorders.
  8. Telemedicine platforms and virtual care services will play an increasingly prominent role in delivering accessible, convenient, and cost-effective insomnia treatment options, particularly in underserved and rural communities.
  9. Regulatory reforms and policy initiatives will streamline approval processes, facilitate market access for innovative insomnia treatment products, and enhance patient safety and quality standards across the healthcare continuum.
  10. The insomnia treatment market will witness significant expansion globally, driven by increasing awareness of sleep disorders, rising healthcare expenditures, and demographic trends such as aging populations and urbanization in emerging economies.

For Table OF Content – Request For Sample Report –

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

Frequently Asked Questions:

What size was the insomnia treatment market in 2023?

The insomnia treatment market reached a valuation of $6,882.91 million in 2023.

What is the compound annual growth rate (CAGR) of the insomnia treatment market?

The CAGR of the insomnia treatment market is 5.44%.

What is the projected size of the insomnia treatment market by 2032?

The market is projected to reach $11,382 million by 2032.

What are the challenges faced by the insomnia treatment market?

Challenges include regulatory hurdles, stigma surrounding mental health, limited insurance coverage, generic competition, and addressing lifestyle and environmental factors.

What is the future outlook for the insomnia treatment market?

The future outlook includes advancements in digital health technologies, personalized medicine approaches, preventive strategies, the expansion of telemedicine, regulatory reforms, and global market expansion driven by demographic trends and technological innovations.

Cancer Profiling Market

Report ID: 36289

Flowable Hemostats Market

Report ID: 36279

Fibrin Sealants Market

Report ID: 36276

Prostate Cancer Market

Report ID: 36273

ECG Telemetry Devices Market

Report ID: 36237

Blotting Systems Market

Report ID: 36233

India Dental Consumables Market

Report ID: 36214

Biotechnology and Pharmaceutical Services Outsourcing Market

Report ID: 36191

India Bariatric Surgery Devices Market

Report ID: 36164

Veterinary Imaging Systems Market

Report ID: 36104

Bioprosthetics Market

Report ID: 36087

Antineoplastic Agents Market

Report ID: 36065

Purchase Options

Delivery Format: Excel.
Designed for the individual purchaser.
Users located at a single corporate site or regional office.
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –


+91 6232 49 3207


24/7 Research Support


– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN